Oral contraceptives and cardiovascular outcomes: Cause or bias?

Contraception

Volumn 62, Issue 2 SUPPL. 1, 2000, Pages

  Spitzer, Walter O ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bias; Bradford Hill; Causal relationship; Confounders; Oral contraceptives; Venous thromboembolism

Indexed keywords

DESOGESTREL; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG SAFETY; EPIDEMIOLOGY; FEMALE; INCIDENCE; ORAL CONTRACEPTION; PUBLIC HEALTH; RISK FACTOR; STROKE; THROMBOEMBOLISM;

BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CAUSALITY; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0033693665     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(00)00149-9     Document Type: Conference Paper

References (49)

1. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components
2. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
3. Third generation oral contraceptives and risk of venous thromboembolic disorders; an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women
4. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
5. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control only study
6. The risks of venous thromboembolic disease amongst German women using oral contraceptives. A database study
7. First-time use of newer oral contraceptives and the risk of venous thromboembolism
8. The environment and disease; association or causation
9. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Group
10. Mortality in relation to smoking; 40 years' observations on male British doctors
11. The use of beta-agonists and the risk of death from asthma
12. The increased risk of venous thromboembolism and the use of third generation progestagens; role of bias in observational research
13. The pill scare revisited; anatomy of a non-epidemic
14. Oral contraceptives and venous thrombosis; different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
15. Oral contraceptives and venous thromboembolism; findings in a large prospective study
16. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
17. Risk of venous thromboembolism in users of hormone replacement therapy
18. Case-control study of venous thromboembolism risk in users of hormone replacement therapy
19. Prospective study of exogenous hormones and risk of pulmonary embolism in women
20. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
21. Hormone replacement therapy and risk of venous thromboembolism; population based case-control study
22. A concurrent cohort study of oral contraceptive users from the VAMP research bank
23. Oral contraceptives and venous thromboembolic disease; status of the current controversy
24. Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third-generation oral contraceptives?
25. Oral contraceptive switching patterns in the United Kingdom; an important potential confounding variable in studies of venous thromboembolism
26. Utilization patterns of oral contraceptives in UK general practice
27. Recent oral contraceptive use patterns in four European countries; evidence for selective prescribing of oral contraceptives containing third generation progestogens
28. Selective prescribing of third generation oral contraceptives (OCs)
29. The role of prescribing and referral bias in studies of the association between third generation oral contraceptives and increased risk of thromboembolism
30. Oral contraceptives and venous thromboembolism
31. Third-generation oral contraceptives and risk of myocardial infarction; an international case-control study
32. Lowered risk of dying of heart attack with third-generation contraceptives may offset risk of dying of thromboembolism
33. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women; results from the Transnational Study on Oral Contraceptives and the Health of Young Women
34. Risk of acute myocardial infarction and low-dose combined oral contraceptives
35. Oral contraceptives and acute myocardial infarction; a case-control study
36. Oral contraceptives and risk of a cerebral thromboembolic attack; results of a case-control study
37. Stroke in users of low-dose oral contraceptives
38. Thrombotic diseases in young women and the influence from oral contraceptives